Characteristics and Management of Patients With Cancer and Atrial Fibrillation: The BLITZ-AF Cancer Registry.
antithrombotic
atrial fibrillation
cancer
comorbidities
oral anticoagulants
Journal
JACC. Advances
ISSN: 2772-963X
Titre abrégé: JACC Adv
Pays: United States
ID NLM: 9918419284106676
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
received:
26
07
2023
revised:
06
12
2023
accepted:
14
02
2024
medline:
12
8
2024
pubmed:
12
8
2024
entrez:
12
8
2024
Statut:
epublish
Résumé
Atrial fibrillation (AF) is a frequent cardiovascular (CV) comorbidity in cancer. The purpose of this study was to examine clinical characteristics and contemporary management of patients with AF and cancer with a specific focus on antithrombotic treatments. This was a prospective, multicenter, observational study of patients with a recent cancer diagnosis and electrocardiographically confirmed AF (the BLITZ-AF Cancer Registry). CHA Overall, 1,514 individuals were enrolled from June 2019 to September 2021 (mean age 74 ± 9 years, 47.5% of participants >75 years of age; 63.5% males). CV diseases were common: 20.9% had heart failure, 18.1% had coronary artery disease, 38.5% had valvular heart disease, and 9.8% had peripheral artery disease. Previous thromboembolic and hemorrhagic events occurred in 13.9% and 10.4% of subjects, respectively. The most common cancer types were lung (14.9%), colorectal (14.1%), prostate (8.8%), and non-Hodgkin lymphoma (8.1%). In total, 41.5% of the patients had a CHA This study demonstrates that there is underuse of appropriate antithrombotic therapy for AF in cancer patients highlighting the need to integrate early CV assessment in the management of these patients. (Non-interventional Study on Patients With Atrial Fibrillation and Cancer [BLITZ-AF Cancer]; NCT03909386).
Sections du résumé
Background
UNASSIGNED
Atrial fibrillation (AF) is a frequent cardiovascular (CV) comorbidity in cancer.
Objectives
UNASSIGNED
The purpose of this study was to examine clinical characteristics and contemporary management of patients with AF and cancer with a specific focus on antithrombotic treatments.
Methods
UNASSIGNED
This was a prospective, multicenter, observational study of patients with a recent cancer diagnosis and electrocardiographically confirmed AF (the BLITZ-AF Cancer Registry). CHA
Results
UNASSIGNED
Overall, 1,514 individuals were enrolled from June 2019 to September 2021 (mean age 74 ± 9 years, 47.5% of participants >75 years of age; 63.5% males). CV diseases were common: 20.9% had heart failure, 18.1% had coronary artery disease, 38.5% had valvular heart disease, and 9.8% had peripheral artery disease. Previous thromboembolic and hemorrhagic events occurred in 13.9% and 10.4% of subjects, respectively. The most common cancer types were lung (14.9%), colorectal (14.1%), prostate (8.8%), and non-Hodgkin lymphoma (8.1%). In total, 41.5% of the patients had a CHA
Conclusions
UNASSIGNED
This study demonstrates that there is underuse of appropriate antithrombotic therapy for AF in cancer patients highlighting the need to integrate early CV assessment in the management of these patients. (Non-interventional Study on Patients With Atrial Fibrillation and Cancer [BLITZ-AF Cancer]; NCT03909386).
Identifiants
pubmed: 39130025
doi: 10.1016/j.jacadv.2024.100991
pii: S2772-963X(24)00179-0
pmc: PMC11312304
doi:
Banques de données
ClinicalTrials.gov
['NCT03909386']
Types de publication
Journal Article
Langues
eng
Pagination
100991Informations de copyright
© 2024 The Authors.
Déclaration de conflit d'intérêts
The study was realized by Heart Care Foundation with own research funds, partially supported by a not conditional grant by Daiichi Sankyo Italia. Dr Ameri received speaker and/or advisor fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Daiichi Sankyo, Janssen, and MSD, all outside the scope of this work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.